Primary Sclerosing Cholangitis
Publication Date: May 1, 2015
RECOMMENDATIONS
Diagnosis
MRCP is preferred over ERCP to establish a diagnosis of PSC. (Strong “We recommend”, Moderate)
317606
Liver biopsy is not necessary to make a diagnosis in patients with suspected PSC based on diagnostic cholangiographics findings. (Conditional (weak) “We suggest”, Low)
317606
Liver biopsy is recommended to make a diagnosis in patients with suspected small duct PSC or to exclude other conditions such as suspected overlap with autoimmune hepatitis. (Conditional (weak) “We suggest”, Moderate)
317606
Antimitochondrial autoantibody testing can help exclude primary biliary cirrhosis. (Conditional (weak) “We suggest”, Moderate)
317606
Patients with PSC should be tested at least once for elevated serum IgG4 levels. (Conditional (weak) “We suggest”, Moderate)
317606
MEDICAL TREATMENT
UDCA in doses >28 mg/kg/day should not be used for management of patients with PSC. (Strong “We recommend”, High)
317606
ENDOSCOPIC MANAGEMENT
ERCP with balloon dilatation is recommended for PSC patients with dominant stricture and pruritus, and/or cholangitis, to relieve symptoms. (Strong “We recommend”, Low)
317606
PSC with a dominant stricture seen on imaging should have an ERCP with cytology, biopsies and FISH to exclude diagnosis of cholangiocarcinoma. (Strong “We recommend”, Low)
317606
PSC patients undergoing ERCP should have antibiotic prophylaxis to prevent post-ERCP cholangitis. (Conditional (weak) “We suggest”, Low)
317606
Routine stenting after dilation of a dominant stricture is not required, whereas short-term stenting may be required in patients with severe stricture. (Conditional (weak) “We suggest”, Low)
317606
LIVER TRANSPLANTATION
Liver transplantation, when possible, is recommended over medical therapy or surgical drainage in PSC patients with decompensated cirrhosis, to prolong survival. (Strong “We recommend”, Moderate)
317606
Patients should be referred for liver transplantation when their MELD score exceeds 14. (Conditional (weak) “We suggest”, Moderate)
317606
PSC AND IBD
Annual colon surveillance preferably with chromoendoscopy is recommended in PSC patients with colitis beginning at the time of PSC diagnosis. (Conditional (weak) “We suggest”, Moderate)
317606
A full colonoscopy with biopsies is recommended in patients with PSC regardless of the presence of symptoms to assess for associated colitis at the time of PSC diagnosis. (Conditional (weak) “We suggest”, Moderate)
317606
Some advocate repeating the exam every 3–5 years in those without prior evidence of colitis. (Conditional (weak) “We suggest”, Low)
317606
HEPATOBILIARY MALIGNANCIES AND GALLBLADDER DISEASE
Consider screening for cholangiocarcinoma with regular cross-sectional imaging with ultrasound or MR and serial CA 19-9 every 6–12 months. (Conditional (weak) “We suggest”, Very low)
317606
Cholecystectomy should be performed for patients with PSC and gallbladder polyps >8 mm, to prevent the development of gallbladder adenocarcinoma. (Conditional (weak) “We suggest”, Very low)
317606
SPECIAL SITUATIONS
Further testing for autoimmune hepatitis is recommended for patients <25 years of age with PSC or those with higher-than-expected levels of aminotransferases usually 5 × upper limit of normal. (Conditional (weak) “We suggest”, Moderate)
317606
MRCP is recommended for patients <25 years of age with autoimmune hepatitis, who have elevated serum ALP usually >2 × the upper limit of normal. (Conditional (weak) “We suggest”, Moderate)
317606
GENERAL MANAGEMENT
Local skin treatment should be performed with emollients and/or antihistamines in patients with PSC and mild pruritus, to reduce symptoms. (Conditional (weak) “We suggest”, Very low)
317606
Bile acid sequestrants such as cholestyramine should be taken (prescribed) in patients with PSC and moderate pruritus, to reduce symptoms. Second-line treatment such as rifampin and naltrexone can be considered if cholestyramine is ineffective or poorly tolerated. (Conditional (weak) “We suggest”, Very low)
317606
Recommend screening for varices in patients with signs of advanced disease with platelet counts <150 × 103/dl. (Conditional (weak) “We suggest”, Very low)
317606
Patients with PSC should undergo BMD screening at diagnosis with dual energy X-ray absorption at diagnosis and repeated at 2- to 4-year intervals. (Conditional (weak) “We suggest”, Moderate)
317606
Patients with advanced liver disease should be screened and monitored for fat-soluble vitamin deficiencies. (Conditional (weak) “We suggest”, Moderate)
317606
Title
Primary Sclerosing Cholangitis
Authoring Organization
American College of Gastroenterology
Publication Month/Year
May 1, 2015
External Publication Status
Published
Country of Publication
US
Document Objectives
This Guideline for clinical practice is intended to indicate preferred approaches to Primary Sclerosing cholangitis as established by scientifically valid research.
Target Patient Population
Patients with primary sclerosing cholangitis
Inclusion Criteria
Female, Male, Adolescent, Adult, Child, Older adult
Health Care Settings
Ambulatory, Hospital, Long term care, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Assessment and screening, Diagnosis, Management, Treatment
Diseases/Conditions (MeSH)
D002761 - Cholangitis, D015209 - Cholangitis, Sclerosing, D014580 - Ursodeoxycholic Acid
Source Citation
Lindor, Keith D MD, FACG; Kowdley, Kris V MD, FACG; Harrison, Edwyn M MD. ACG Clinical Guideline: Primary Sclerosing Cholangitis, American Journal of Gastroenterology: May 2015 - Volume 110 - Issue 5 - p 646-659 doi: 10.1038/ajg.2015.112